<DOC>
	<DOC>NCT02784002</DOC>
	<brief_summary>The purpose of this research study is to evaluate the safety and effectiveness of Ridinilazole (SMT19969) in treating C. difficile Infection (CDI).</brief_summary>
	<brief_title>A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<criteria>Informed Consent Clinical diagnosis of CDI plus laboratory diagnostic test No more than 30 hours antimicrobial treatment for current CDI episode Female subjects of childbearing potential must use adequate contraception Lifethreatening or fulminant CDI Subjects with 2 or more episodes of CDI in the previous year Females who are pregnant or breastfeeding History of inflammatory bowel disease Coadministration of potent Pglycoprotein inhibitors Participation in other Clinical research studies within one month of screening Subjects that the Investigator feels are inappropriate for the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>